AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The biopharma giant has also set up a $1 billion fund to foster biotech innovation in that country. The move will see the AstraZeneca found a global R&D center in Shanghai’s central Jing’an district. The company currently operates R&D centers at its Cambridge, UK, headquarters as well as at sites in Maryland and Sweden. The new China facility will carry out R&D for innovative drugs, with the focus being on diseases that are prevalent in China. The site will bring AstraZeneca’s R&D headcount in China to 1,000 people. The industry leaders says it has no plans to co-locate all China R&D facilities. Learn More